InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,004.79
(
0.53%
)
US TECH 100
20,559.21
(
0.09%
)
Dow Jones
44,014.30
(
0.65%
)
Brent Oil
73.72
(
-2.31%
)
Bitcoin
76,928.22
(
1.35%
)

Replies to post #217327 on Biotech Values

Replies to #217327 on Biotech Values
icon url

Bickema

02/16/18 10:25 AM

#217330 RE: DewDiligence #217327

Marching towards your 4 billion number, thanks Dew.
icon url

Bickema

02/20/18 12:53 PM

#217378 RE: DewDiligence #217327

Dew any reason to think Mavyret can't capture 70-80% market share? It has already blown past analysts expectations and is showing no signs of slowing down.
icon url

DewDiligence

02/23/18 1:10 PM

#217462 RE: DewDiligence #217327

ENTA—Mavyret scripts plateaued in the week ending 2/16/18, showing 0.2% growth in NRx and 0.9% growth in TRx (according to IMS).

ABBV’s patient share for the week was 37.7% for NRx and 33.5% for TRx, both down slightly from the prior week (#msg-138602647).

Do these data mean that Mavyret's growth trajectory in the US market has materially changed? It's too soon to say, but I strongly doubt that.